10月22日，Summit Therapeutics PLC盘前下跌5.24%，报15.0美元/股，成交额20.53万美元。
消息面上，公司宣布将与ECOG-ACRIN Cancer Research Group合作开展一项II/III期临床试验，评估Ivonescimab用于晚期胆道癌一线治疗。
该研究将比较Ivonescimab联合吉西他滨和顺铂化疗，与帕博利珠单抗或度伐利尤单抗联合相同化疗方案的效果，主要终点为总生存期，试验中心预计于第四季度开始开放。此前该药物在中国开展的晚期胆道癌III期研究已达到总生存期、无进展生存期和客观缓解率等终点，本次合作意味着其全球临床推进进一步落地。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.